Core Viewpoint - The announcement by Yuan Da Pharmaceutical (0512.HK) indicates a significant advancement in the development of domestic antidepressant drugs, with their innovative traditional Chinese medicine GPN01360 successfully reaching clinical endpoints in Phase II trials, showing notable efficacy and safety advantages for treating depression in China [1] Group 1 - The Phase II clinical study of GPN01360 has successfully achieved its clinical endpoints [1] - The product demonstrates significant efficacy and safety advantages [1] - GPN01360 is expected to become a new treatment option for depression patients in China [1] Group 2 - This development represents a major progress in the research and development of domestic antidepressant medications [1] - The success of GPN01360 contributes to the global treatment landscape for depression, showcasing China's capabilities in this field [1]